Guillo Lucas, D'Amico Ferdinando, Achit Hamza, Ayav Carole, Guillemin Francis, Danese Silvio, Frimat Luc, Peyrin-Biroulet Laurent
Department of Gastroenterology and Inserm NGERE U1256, University Hospital of Nancy, University of Lorraine, Vandoeuvre-lès-Nancy, France; Department of Gastroenterology, University Hospital of Marseille Nord, University of Aix-Marseille, Marseille, France.
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Dig Liver Dis. 2021 Jun;53(6):691-696. doi: 10.1016/j.dld.2021.01.015. Epub 2021 Feb 6.
The kidney function monitoring is recommended in routine practice to detect 5-aminosalicylic acid (5-ASA) related nephrotoxicity, although is not standardized. The optimal monitoring is unknown, especially the best timing and which tests to perform. We summarized why, how, and when to perform the monitoring for patients treated with 5-ASA and provided an overview of the current guidelines on this topic.
Relevant studies on this topic were searched in PubMed, Embase, and Web of Science databases from July to August 2020.
Serum creatinine, the estimated glomerular filtration rate, and 24-h proteinuria are the 3 main tests used for the monitoring in daily practice. Regarding the timing, several monitoring strategies have been proposed and guidelines are available too, but they provide conflicting information. To date, there is no medical evidence-based that one strategy is better than another. Comorbidities, chronic renal disease, use of nephrotoxic drugs or concomitant steroid therapy also impact the nephrotoxicity risk. Based on the literature review we proposed a kidney function monitoring strategy to guide physicians in clinical practice.
A baseline assessment should be performed in all patients treated with 5-ASA. The monitoring should be carried out according to the other nephrotoxic factors. A tight monitoring may reduce morbidity and mortality of drug nephrotoxicity.
尽管未标准化,但在常规实践中建议进行肾功能监测以检测5-氨基水杨酸(5-ASA)相关的肾毒性。最佳监测方法尚不清楚,尤其是最佳时机和应进行哪些检测。我们总结了对接受5-ASA治疗的患者进行监测的原因、方法和时间,并概述了关于该主题的当前指南。
2020年7月至8月在PubMed、Embase和Web of Science数据库中检索了关于该主题的相关研究。
血清肌酐、估算肾小球滤过率和24小时蛋白尿是日常实践中用于监测的3项主要检测。关于监测时机,已经提出了几种监测策略,也有相关指南,但它们提供的信息相互矛盾。迄今为止,尚无基于医学证据表明一种策略优于另一种。合并症、慢性肾病、使用肾毒性药物或同时进行类固醇治疗也会影响肾毒性风险。基于文献综述,我们提出了一种肾功能监测策略,以指导临床医生的实践。
所有接受5-ASA治疗的患者均应进行基线评估。应根据其他肾毒性因素进行监测。严密监测可能会降低药物肾毒性的发病率和死亡率。